Agios Pharmaceuticals, Inc. (AGIO)
$
29.2
+0.16 (0.55%)
Key metrics
Financial statements
Free cash flow per share
-7.1224
Market cap
1.7 Billion
Price to sales ratio
38.0157
Debt to equity
0.0347
Current ratio
13.8196
Income quality
1.0216
Average inventory
31.4 Million
ROE
-0.2835
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering and developing medicines within the realm of cellular metabolism and related biological areas. The company delivers pivotal treatments such as PYRUKYND (mitapivat), an activator for both wild-type and various mutant pyruvate kinase (PK) enzymes targeted at addressing hemolytic anemias. Additionally, Agios is advancing AG-946, currently in Phase I clinical studies for treating hemolytic anemias and other medical indications. Financially, the company earned an interest income of $48,083,000.00 showcasing its strategic financial investments. The income before tax ratio is 19.67 reflecting the pre-tax margin and indicating a robust operational capacity. However, the net total of other income and expenses is $1,143,706,000.00 which illustrates the influence of non-core financial activities on the overall financial picture. Moreover, the company reported depreciation and amortization expenses of $5,653,000.00 which reflect the wear and tear of its physical and intangible assets. The gross profit ratio is 0.89 indicating the efficiency of the company's production and sales operations in maintaining profitability while advancing its innovative drug portfolio. As a notable entity in the biopharmaceutical landscape, Agios Pharmaceuticals operates within a mid-range market capitalization of $1,702,763,310.00 positioning itself as a steady performer in the industry. The stock is affordable at $37.70 making it suitable for budget-conscious investors looking to engage in this sector. Additionally, the stock has an average trading volume of 1,193,528.00 indicating moderate liquidity, which is essential for investors considering market entry. It is a key player in the biopharmaceutical industry, contributing significantly to the overall market landscape and driving forward innovation and growth. Positioned within the Healthcare sector, Agios Pharmaceuticals reflects a commitment to advancing healthcare solutions while fostering economic stability through its strategic investment and operational initiatives.
Is Agios Pharmaceuticals, Inc. (AGIO) a good investment?
Investing in Agios Pharmaceuticals, Inc. (AGIO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Agios Pharmaceuticals, Inc. (AGIO)'s stock forecast?
Analysts predict Agios Pharmaceuticals, Inc. stock to fluctuate between $22.24 (low) and $62.45 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Agios Pharmaceuticals, Inc.'s market capitalization?
As of 2025-11-28, Agios Pharmaceuticals, Inc.'s market cap is $1,702,763,310, based on 58,313,812 outstanding shares.
How does Agios Pharmaceuticals, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Agios Pharmaceuticals, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Agios Pharmaceuticals, Inc. (AGIO) stock?
To buy Agios Pharmaceuticals, Inc. (AGIO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AGIO. Place an order (Market, Limit, etc.).
What is the best time to invest in Agios Pharmaceuticals, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Agios Pharmaceuticals, Inc. perform in the last earnings report?
Revenue: $36,498,000 | EPS: $11.86 | Growth: -287.36%.
Where can I find Agios Pharmaceuticals, Inc.'s investor relations reports?
Visit https://www.agios.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Agios Pharmaceuticals, Inc.?
You can explore historical data from here
What is the all-time high and low for Agios Pharmaceuticals, Inc. stock?
All-time high: $62.58 (2024-11-11) | All-time low: $16.75 (2022-06-16).
What are the key trends affecting Agios Pharmaceuticals, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.
seekingalpha.com
Agios Pharmaceuticals, Inc. ( AGIO ) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease November 19, 2025 8:00 AM EST Company Participants Morgan Sanford Brian Goff - CEO & Director Sarah Gheuens - Chief Medical Officer and Head of Research & Development Tsveta Milanova - Chief Commercial Officer Conference Call Participants Biree Andemariam Eric Schmidt - Cantor Fitzgerald & Co., Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Ellen Horste - TD Cowen, Research Division Alec Stranahan - BofA Securities, Research Division Emily Bodnar - H.C. Wainwright & Co, LLC, Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Luca Issi - RBC Capital Markets, Research Division Presentation Operator Good morning, and welcome to the Agios Pharmaceuticals Investor Conference Call and Webcast.
benzinga.com
Agios Pharmaceuticals Inc. (NASDAQ: AGIO) stock plunged on Wednesday after the company released topline results from RISE UP Phase 3 data for mitapivat in sickle cell disease.
reuters.com
Agios Pharmaceuticals said on Wednesday its sickle cell drug met one of its two main goals in a late-stage study of patients aged 16 and older, but failed to show a statistically significant reduction in pain crises.
seekingalpha.com
Agios Pharmaceuticals delivered strong Q3'25 results, with revenue up 44% year-over-year and continued momentum in its rare-disease pipeline. AGIO's key catalysts include the FDA decision on Pyrukynd's thalassemia sNDA in December 2025 and topline data from the 'RISE UP' sickle cell trial. Despite premium valuation, the company maintains a robust balance sheet and is positioned for significant growth if regulatory approvals and market expansion materialize.
zacks.com
Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.
seekingalpha.com
Agios Pharmaceuticals, Inc. ( AGIO ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Morgan Sanford Brian Goff - CEO & Director Cecilia Jones - Chief Financial Officer Tsveta Milanova - Chief Commercial Officer Sarah Gheuens - Chief Medical Officer and Head of Research & Development Conference Call Participants Eric Schmidt - Cantor Fitzgerald & Co., Research Division Alec Stranahan - BofA Securities, Research Division Marc Frahm - TD Cowen, Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Presentation Operator Good morning, and welcome to Agios Pharmaceuticals Third Quarter 2025 Conference Call. [Operator Instructions] Please be advised that this call is being recorded at Agios' request.
zacks.com
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.78 per share versus the Zacks Consensus Estimate of a loss of $1.93. This compares to earnings of $4.2 per share a year ago.
globenewswire.com
$12.9 million in third quarter PYRUKYND® (mitapivat) net revenues PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025 CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision expected by early 2026 RISE UP Phase 3 trial topline results in sickle cell disease by year-end; potential U.S. commercial launch in 2026 Phase 2b tebapivat trial in lower-risk MDS fully enrolled; topline results expected in early 2026 $1.3 billion dollars in cash, cash equivalents and marketable securities as of September 30, 2025 CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the third quarter ended September 30, 2025.
prnewswire.com
NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
See all news
